180. Metastatic NSCLC feat. KRAS and MET mutations
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
180. Metastatic NSCLC feat. KRAS and MET mutations
-
Narrated by:
-
By:
About this listen
On this week's episode, Josh and Michael exchange the established treatment landscape of EGFR and ALK mutant NSCLC for the developing management of disease harbouring KRAS and MET mutations. The most common mutation meets one of the least common in this battle of therapeutic tenacity.
Studies discussed in this episode:
INSIGHT-2
KRYSTAL-12
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.
Hosted on Acast. See acast.com/privacy for more information.